Inhibition of arginine- and hypoglycemia- induced growth hormone release by acetate in dialyzed patients.
We have previously demonstrated that acetate suppresses the basal hypersecretion of growth hormone in diabetic and non-diabetic uremic patients. The present study was designed to clarify the potency and characteristics of the growth hormone suppressive effect of acetate by applying two powerful growth hormone stimuli: arginine infusion and insulin hypoglycemia. In four non-diabetic uremic and three diabetic uremic subjects, arginine infusion caused a rise in plasma growth hormone to 22.8 +/- 3.3 ng/ml and 22.0 +/- 5.6 ng/ml (mean +/- SEM, P less than 0.05). During hemodialysis against acetate buffered dialysis fluid and during a simultaneous acetate infusion, the response to arginine infusion was almost completely inhibited in both groups. In four uremic subjects insulin hypoglycemia elicited an increase in plasma growth hormone to 30.0 +/- 7.0 ng/ml (mean +/- SEM, P less than 0.05). During hemodialysis and acetate infusion the response to insulin hypoglycemia was again almost abolished. The glucagon and insulin responses were unaffected by hemodialysis as well as by acetate infusion. The results demonstrate the high degree of efficiency of the acetate induced growth hormone suppression comparable to that of glucose.
D000085:Acetates / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D001120:Arginine / Q000494:pharmacology*; D003928:Diabetic Nephropathies / Q000150:complications; D005260:Female; D013006:Growth Hormone / Q000037:antagonists & inhibitors* / Q000097:blood / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D014511:Uremia / Q000209:etiology / Q000378:metabolism / Q000628:therapy*
D000085:Acetates; D013006:Growth Hormone; D001120:Arginine